Thomas E. Hutson
0000-0002-4529-4212
Publication & Citation Trends
Publications
0 total
Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.
Cited by 0
Semantic Scholar
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study OA
Cited by 2
Semantic Scholar
Re: Justine Panian, Caiwei Zhong, Sharon H. Choi, et al. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.11.011.
Cited by 0
Semantic Scholar
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Cited by 1
Semantic Scholar
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
Cited by 1
Semantic Scholar
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Cited by 9
Semantic Scholar
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study OA
Cited by 93
Semantic Scholar
A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
Cited by 0
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(307)
Cancer Genomics and Diagnostics
(116)
Renal and related cancers
(97)
Cancer Immunotherapy and Biomarkers
(53)
Economic and Financial Impacts of Cancer
(49)
Affiliations
Privolzhsky Research Medical University
University of Siena
Texas Tech University
Texas A&M Health Science Center
National Health Service